Convalescent plasma use in pregnant patients with COVID19 related ARDS: a case report and literature review

Gullo, G.; Cucinella, Gaspare; Tumminello, Mario; Renda, B.; Donzelli, M.; Bue, V. Lo; Termini, Donatella; Maranto, Marianna; Tommasi, O. De; Tarantino, F.

doi:10.36129/jog.2022.32

Cited by 4 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A systematic review of a small sample of 6 early pandemic studies shows that, although vertical transmission of severe acute respiratory syndrome arising from coronavirus infection has so far been ruled out, and maternal and neonatal outcomes have been favorable overall, preterm delivery rates by cesarean section are still worrisome [ 30 ]. In any case, COVID-19, which is linked to respiratory insufficiency in late pregnancies, can undoubtedly give rise to a complex clinical scenario [ 6 , 31 ].…”

Section: Discussionmentioning

confidence: 99%

“…Deaths have been reported equally in pregnant and non-pregnant women of reproductive age [ 4 ]. Among pregnant women, especially those who develop COVID-19 pneumonia, there is an increased risk of preeclampsia, preterm, and cesarean delivery due to fever and hypoxemia [ 5 , 6 ]. In this regard, it is worth mentioning a multinational cohort study which enrolled a total of 2130 women during the first phase of the pandemic, 706 of whom had COVID-19 and 1424 who were uninfected.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Symptomatic COVID-19 in Pregnancy: Hospital Cohort Data between May 2020 and April 2021, Risk Factors and Medicolegal Implications

et al. 2023

View full text Add to dashboard Cite

Pregnancy does not appear to increase susceptibility to SARS-CoV-2 infection, but some physiological changes, such as the reduction of residual functional volumes, elevation of the diaphragm, and impaired cellular immunity, may increase the risk of severe disease and result in a higher risk of complications. The article’s primary objective is to evaluate the factors associated with symptomatic COVID-19 disease in pregnancy. The secondary objective is to describe maternal and neonatal outcomes and cases of vertical transmission of the infection. All pregnant women hospitalized with SARS-CoV2 infection were included in a prospective study in the UOC of Obstetrics and Gynecology, AOOR Villa Sofia—Cervello, Palermo, between May 2020 and April 2021. The patients who requested the termination of the pregnancy according to Law 194/78 were excluded. We included 165 pregnancies with a total number of 134 deliveries. Overall, 88.5% of the patients were asymptomatic at the time of admission and 11.5% were symptomatic. Of them, 1.8% of the patients required hospital admission in the intensive care unit. Symptoms occurrences were positively associated with the increase in maternal BMI (OR 1.17; p = 0.002), the prematurity (OR 4.71; p = 0.022), and at a lower birth weight (OR 0.99; p = 0.007). One infant tested positive for SARS-CoV2 nasopharyngeal swab; 11.4% of newborns had IgG anti SARS-CoV2 at birth; IgM was positive in 2.4% of newborns. There was no difference statistically significant difference in the vertical transmission of the infection among the group of symptomatic pregnant women and that of asymptomatic pregnant women.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Symptomatic COVID-19 in Pregnancy: Hospital Cohort Data between May 2020 and April 2021, Risk Factors and Medicolegal Implications

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Pregnant women with COVID-19 were identified as a vulnerable or higher risk population as well, since they are at increased risk of developing severe illness, hospitalization, admission to intensive care unit (ICU) and death compared with non-pregnant women [ 4 , 5 , 6 ]. A multinational observational study conducted in 18 countries showed that pregnant women with a diagnosis of COVID-19 had a greater risk of admission to the ICU or high-dependency unit (RR, 5.04; 95% CI, 3.13–8.10) and were 22 times more likely to die (RR, 22.3; 95% CI, 2.88–172) [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Factors Associated with Anti-SARS-CoV-2 Vaccine Acceptance among Pregnant Women: Data from Outpatient Women Experiencing High-Risk Pregnancy

et al. 2023

View full text Add to dashboard Cite

Pregnant women are at higher risk of severe Coronavirus disease 2019 (COVID-19) complications than non-pregnant women. The initial exclusion of pregnant women from anti-SARS-CoV-2 vaccines clinical trials has caused a lack of conclusive data about safety and efficacy for this vulnerable population. This cross-sectional study aims to define the factors related to vaccination adherence in a sample of women experiencing high-risk pregnancies. The recruited women completed a questionnaire based on the Health Belief Model. Data were analyzed to evaluate the associations between socio-demographic variables and vaccination acceptance through descriptive, univariate and multivariate logistic analyses. Among the 233 women enrolled, 65.2% (n = 152) declared that they would accept the anti-SARS-CoV-2 vaccine. Multivariate analysis showed that vaccination acceptance was associated with a high educational level (aOR = 4.52, p = 0.001), a low perception of barriers to vaccination (aOR = 1.58, p = 0.005) and the gynecologist’s advice (aOR = 3.18, p = 0.01). About a third of pregnant women are still hesitant about the anti-SARS-CoV-2 vaccine, probably because of the conflicting information received from media, friends, acquaintances and health institutions. Determining factors linked to vaccine hesitancy among pregnant women is useful for creating vaccination strategies that increase vaccination uptake.

show abstract

“… The results demonstrate that, in the absence of specific adverse effects, early CCP Tx in patients with severe COVID-19 may contribute to a satisfactory result, with reduced mortality. Giuseppe Gullo et al 141 CR and literature review on the usage of CP in women who are pregnant and have ARDS related to COVID-19 (CR) 34-year-old multipara woman with 27 weeks and 4th day of gestation. CP administration After a total of 43 days, the patient was discharged in good general health, apyretic, and without any respiratory symptoms or signs.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review

Kandula¹,

Tuji²,

Gudeta³

et al. 2023

JBM

View full text Add to dashboard Cite

Worldwide pandemic with coronavirus disease-2019 (COVID-19) was caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). As November 2, 2022, World Health Organization (WHO) received 628,035,553 reported incidents on COVID-19, with 6,572,800 mortalities and, with a total 12,850,970,971 vaccine doses have been delivered as of October 31, 2022. The infection can cause mild or self-limiting symptoms of pulmonary and severe infections or death may be caused by SARS-CoV-2 infection. Simultaneously, antivirals, corticosteroids, immunological treatments, antibiotics, and anticoagulants have been proposed as potential medicines to cure COVID-19 affected patients. Among these initial treatments, COVID-19 convalescent plasma (CCP), which was retrieved from COVID-19 recovered patients to be used as passive immune therapy, in which antibodies from cured patients were given to infected patients to prevent illness. Such treatment has yielded the best results in earlier with preventative or early stages of illness. Convalescent plasma (CP) is the first treatment available when infectious disease initially appears, although few randomized controlled trials (RCTs) were conducted to evaluate its effectiveness. The historical record suggests with potential benefit for other respiratory infections, as coronaviruses like Severe Acute Respiratory Syndrome-CoV-I (SARS-CoV-I) and Middle Eastern Respiratory Syndrome (MERS), though the analysis of such research is constrained by some non-randomized experiments (NREs). Rigorous studies on CP are made more demanding by the following with the immediacy of the epidemics, CP use may restrict the ability to utilize it for clinical testing, non-homogenous nature of product, highly decentralized manufacturing process; constraints with capacity to measure biologic function, ultimate availability of substitute therapies, as antivirals, purified immune globulins, or monoclonal antibodies. Though, it is still not clear how effectively CCP works among hospitalized COVID-19 patients. The current review tries to focus on its efficiency and usage in clinical scenarios and identifying existing benefits of implementation during pandemic or how it may assist with future pandemic preventions.

show abstract

Convalescent plasma use in pregnant patients with COVID19 related ARDS: a case report and literature review

Cited by 4 publications

References 38 publications

Symptomatic COVID-19 in Pregnancy: Hospital Cohort Data between May 2020 and April 2021, Risk Factors and Medicolegal Implications

Symptomatic COVID-19 in Pregnancy: Hospital Cohort Data between May 2020 and April 2021, Risk Factors and Medicolegal Implications

Factors Associated with Anti-SARS-CoV-2 Vaccine Acceptance among Pregnant Women: Data from Outpatient Women Experiencing High-Risk Pregnancy

Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review

Contact Info

Product

Resources

About